Xenetic Bio Share Discussion Threads

[buywell2] 13/8/2014 08:10

Wondered about the rise to $1 the other day

This first low dose test Indicates efficacy is now a given methinks and the second set of results should be better still.

The results agree with those previously obtained in India.

''Even at the lowest dose levels being administered twenty five percent (25%) of the cohort's patients reached the target 10-12 g/dL hemoglobin levels.''



August 11, 2014

Xenetic Biosciences Announces Ongoing Safety and Efficacy Data from Phase 2 Trial of ErepoXen®

Xenetic Biosciences, Inc. (OTCBB: XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces results from its ongoing data analysis of its Phase 2 ErepoXen® clinical trial being conducted in Australia and New Zealand.

This is a sequential multiple-dose study evaluating the safety and efficacy of subcutaneously administered ErepoXen® (PSA-EPO, a polysialylated erythropoietin), for the treatment of anemia in Chronic Kidney Disease (CKD) patients who are neither on dialysis nor receiving erythropoiesis stimulating agents.We now report on the results of the first cohort of 12 patients who have all completed treatment with ErepoXen® at the lowest dose level.

All enrolled patients in the cohort completed the trial and ErepoXen® was found to be safe and well tolerated with no drug-related serious adverse events.

Even at the lowest dose levels being administered twenty five percent (25%) of the cohort's patients reached the target 10-12 g/dL hemoglobin levels.

This open-label, sequential multiple dose finding study is designed to determine the dose of ErepoXen® that is safe and moves the patient's hemoglobin level into the 10-12 g/dL range.

No serious adverse events were reported in the 12 patients evaluated. Gastrointestinal disorders and infections of mild to moderate intensity were the most common events and were reported by 4 patients.

None of the events were assessed as being related to the study drug. In addition, there was no indication of antibody formation against polysialic acid (PSA), EPO or PSA-EPO in any of the subjects tested to date.

These are the first data on repeat dosing of PSA-EPO in human subjects demonstrating its tolerability, safety and efficacy in Western clinical trials.

The second cohort on a higher dose level is currently being administered ErepoXen®.On the basis of this data, a review carried out in July resulted in the Safety Review Committee authorizing a dose increase for the third cohort of the study, which is scheduled to start in September.

The Safety Review Committee intends to meet again in Q4 of 2014, and the Company expects to announce further trial results shortly hereafter.

These results are very encouraging and are in agreement with the data from the other 96 subjects that have already been administered ErepoXen® during trials in India. We are delighted that ErepoXen® is performing well in this pivotal Western clinical trial.

''This new efficacy data demonstrates that we have a drug that could well allow the Company to make a major impact on the $7Bn global anemia market'' said Scott Maguire, Chief Executive Officer of Xenetic. ''

''We look forward to receiving the data on the additional cohorts at higher dose ranges to hopefully confirm the therapeutic value of ErepoXen®.

We plan to seek a commercial partner with the resources to bring this large market drug candidate through late-stage clinical development and potential market launch.

[tradejunkie2] 11/8/2014 14:36

Ha ha buywell trades PENNY dogs!!!

[corrientes] 29/7/2014 17:47

Oops, but really a bit meaningless.

[corrientes] 02/7/2014 16:15

No intention of selling buywell2 and holly dog, and on reflection I think the spreads on the OTC must be diabolical, so Pershing used any old excuse to avoid having to do anything about it. So far, it seems no major impediment and steady as she goes. Not a one trick pony

Thanks.

[holly_dog] 02/7/2014 13:55

Corrientes - as buywell has said, unless you need cash wait until NASDAQ. You will be clobbered on price you get, fees and also more news is in the pipeline to come soon. I think we will see another re rating off NASDAQ as there is a liquidity discount being applied here and rightly so.

Waiting another few months will make a big difference to the returns we'll see in my opinion. Personally this is just the start of the journey - would be aiming for a 5 year hold and big capital appreciation provided the story doesn't change. An EPO outlicense deal, NASDAQ and Onco in the lab stateside would get us towards $3 I believe, and all that is feasible by year end.

[buywell2] 02/7/2014 09:05

Wait for the listing to NASDAQ

More results data will be out by then and the share price should be over $1

Failing that email Colin Hill and tell him you have shares you would like to sell

I believe several USA Institutions want shares in quantity but can't get any

If enough smaller UK investors put theirs together in a package , thro Xenetic and their contacts , then a deal can be done.





Not wise to sell now though in my humble opinion .... when full ErepoXen trials news comes out in a few months the EFFICACY data should ensure a good upfront fee to out-licence it.

Other OncoHist news by then should also push XBIO higher

Selling then if you need to via NASDAQ will be a piece of cake and cheaper

If however OncoHist is a success in AML and gets other cancer Orphan status granted , Xenetic intend to develop these themselves.

Thus far things are looking VERY good

The head Scientist at Dana Faber has said that Xenetics OncoHist technology is the BEST he has seen in over 20 years.

It has shown to have applications to both Lymphomas and various types of Leukemia PLUS it shows to have possible use in 60 out of 100 different cancer types by the way it specifically targets and kills tumour cells and does NOT damage good cells.

$10 a share within 5 years is doable is my take

[corrientes] 01/7/2014 14:43

I have about 24,000 XBIO shares, which I recently wanted my broker,Pershing, to put into nominee name to expedite a smooth and speedy sale when the time is right !

This they refuse to do as the share price 'falls well below what they can take in' whatever that vague statement means. On further enquiry it transpires that they need .2 of a $ when they require .5 of a $, a statement which again doesn't make a lot of sense to me anyway,particularly given the present share price.

Xenetic themselves when transferring to OTC, recommended a firm called Glendale Securities of Sherman Oaks CA for disposals, but comments about them have not exactly been flattering and I suspect they wouldn't be cheap to deal with.

I know that spreads and costs would make this an expensive share to sell at any point, and anyway I intend to remain a holder. The broker is going to send the share certificate back to me.

Has anyone here got any suggestions as to the best course of action ?

[buywell2] 30/6/2014 17:14

....................... GOOD NEWS and MORE TO COME ......................


Xenetic Biosciences Announces Ongoing Safety Data From Phase 2 Trial of ErepoXen

LEXINGTON, Mass., June 30, 2014 (GLOBE NEWSWIRE) --

Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced results from its ongoing data analysis of the first cohort of its Phase 2, sequential multiple dose study evaluating the safety and efficacy of ErepoXen®, subcutaneously administered polysialylated erythropoietin (PSA-EPO), for the treatment of anemia in Chronic Kidney Disease (CKD) patients who are neither on dialysis nor receiving erythropoiesis stimulating agents.

ErepoXen® was found safe and well tolerated to date, with no serious adverse events. This is the first data on repeat dosing of PSA-EPO in human subjects demonstrating its tolerability and safety in Western clinical trials. On this basis, the Safety Review Committee authorized a dose increase for the second cohort of the study, which is currently underway and demonstrating early signs of clinical efficacy.

The Safety Review Committee intends to meet again in August 2014, and the Company expects additional results to be available in the third quarter of 2014.

"We are very pleased to announce these safety and tolerability data for ErepoXen®, our most advanced product candidate," said Scott Maguire, Chief Executive Officer of Xenetic.

"This trial represents one of many currently on-going studies of the compound, and supports our continued testing of ErepoXen® as a potential treatment option for anemic patients in need of more effective therapies. We expect to seek a commercial partner to assist us in bringing this large market drug candidate through late stage clinical development and potential market launch."

ErepoXen® is an improved, polysialylated form of erythropoietin (EPO), a hormone produced by the kidneys to maintain red blood cell production and prevent anemia. ErepoXen® is designed to reduce the required frequency of dosage and side effects, and to be less immunogenic than existing treatments.
This open-label, sequential multiple dose finding study is designed to determine the dose of ErepoXen® that is safe and moves the patient's hemoglobin level into the 10-12 g/dL range.

No serious adverse events were reported in the 15 patients evaluated. Gastrointestinal disorders and infections of mild to moderate intensity were reported by 13 patients.

None of the events were assessed as being related to the study drug.

In addition there is no indication of antibody formation against polysialic acid (PSA), EPO or PSA-EPO in any of the subjects tested to date.

[buywell2] 30/6/2014 11:29

"If this molecule works, we have a multi-billion dollar drug on our hands"



.................... GOOD THINGS COMING FOR XENETIC .....................


Use Flash link after entering details to listen


Reasons to be cheerful part 1 2 and 3


Part 1

Science & Technology

OncoHist


OncoHist™ is based on research related to the novel functions of histones. Histone H1 has strong anti-proliferative properties against cancer cells of different histological origin. This has been demonstrated extensively for hematologic malignancies, such as leukemias, lymphomas and myelomas, and also for tumors from other tissues. Susceptibility of cells to the cytotoxic effect of histones is determined by the ability of histone H1 to selectively destabilize the tumor cell membrane, which results in cell death.

OncoHist exhibits the same properties as naturally occurring histone H1.3 molecules and therefore has low immunogenicity and antigenicity. Extensive data suggest that OncoHist molecules have the ability to selectively destabilize the tumor cell membrane, which instigates cell death. The selective attack of the tumor cell membrane is due to OncoHist molecules' ability to recognize the difference in membrane structure between tumor cells and their healthy counterparts.

OncoHist is being investigated for certain potential advantages over conventional cancer therapeutics in the areas of selectivity, toxicity, induction of resistance and immunogenicity.

A pilot clinical study (phase I/II) with Acute Myeloid Leukemia (AML) patients was performed at the Saarland University Hospital at Homburg/Saar, Germany. OncoHist was safe and well tolerated in this study. Clinical effects were noted in seven patients with three partial remissions. Most notably, two patients who received two treatment cycles each experienced stabilization of their disease for 7 and 17 months. A clinical trial of 120 AML patients is underway in the Russian Federation. This trial aims to examine the benefits of OncoHist in combination with standard therapy: cytarabine with mitoxantrone. An additional NHL trial has been initiated in Russia.

OncoHist has been granted orphan drug status for AML by both the FDA and EMA and for Acute Lymphocytic Leukemia (ALL) in Europe by the EMA.



Part 2

Xenetic Biosciences chief excited about OncoHist potential

21st Jun 2013, 4:36 am by Giles Gwinnett

Maguire said all three of the firm's technologies - MyeloXen, for multiple sclerosis, ErepoXen for anaemia, and OncoHist - were in at least phase 2 clinical trials

Maguire said all three of the firm's technologies - MyeloXen, for multiple sclerosis, ErepoXen for anaemia, and OncoHist - were in at least phase 2 clinical trials

Xenetic Biosciences (LON:XEN) chief executive Scott Maguire said he was " particularly excited" about the potential of the firm's OncoHist drug candidate for acute myeloid leukaemia.

In a conference call, prior to the biotech's AGM on June 28, Maguire said the drug was "seemingly a non-toxic therapy" for leukaemia, having not yet reached a maximum tolerated dose in clinical trials - something which was unheard of for a cancer therapy.

"If this molecule works, we have a multi-billion dollar drug on our hands," he told the call.

Maguire said all three of the firm's technologies - MyeloXen, for multiple sclerosis, ErepoXen for anaemia, and OncoHist - were in at least phase 2 clinical trials.

None have shown as yet any serious adverse effects, he said, and the firm was seeing "excellent efficacy" results with ErepoXen.

In its 2012 results, released on June 6, the firm said key drivers in the short term will be the start of phase II trials for ErepoXen in Australia this summer and the phase II data from OncoHist.

Maguire also updated today on the firm's Boston expansion plans, saying an experienced team will be place in the labs and offices in September this year.

The firm is locating its lab and development operations in Boston as it is a world leading centre for orphan drug development and commericalisation, said Maguire.







Part 3


"Looking ahead to the remainder of 2014, our priority is advancing OncoHist® for refractory and relapsed Acute Myeloid Leukemia (AML) into a U.S. FDA clinical trial, as well as focusing on our most advanced clinical candidate, ErepoXen® for the treatment of anemia. In parallel, we will be receiving patient data on a number of candidates from our Russian partners, which will provide the Company further U.S. pipeline expansion opportunities."

[buywell2] 25/6/2014 07:16

I believe that several brokers are now more aware of what Xenetic are about

The ErepoXen clinical trials news is imminent

The pedal needs applying to the metal now when they get released.

Positive RNS's and News-flow supported by an increasing number of Investor presentations and road shows

Plus with some paid advertising , radio and TV , investor publications and the like , should be considered ... it is America after all.

The more that America gets to here about Xenetic , the more money we are likely to get for out licensing ErepoXen ........ I want an auction

[holly_dog] 24/6/2014 21:36

125k volume today, highest on record. That's 4 big volume days in a row, holding onto these levels which is promising. Watching L2 it still looks like MMs are trying to hold us in the 90s.

NASDAQ and Aus news and we will smash back into a new range.

Let's see what tomorrow brings. Finally it looks like we are out of the doldrums. Absolutely clear that US investors are now buying in properly.

[buywell2] 24/6/2014 16:46

Things are now moving FAST

Investor Relations

Press Releases














Jun 11, 2014
Xenetic Biosciences Announces Dosing of First Patient on Dialysis in Phase 2a Clinical Study of ErepoXen(R)

LEXINGTON, Mass., June 11, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announced today that its partner, the Serum Institute of India, has dosed the first patient in the second cohort of a Phase 2a clinical, sequent...



Jun 9, 2014
Xenetic Biosciences Strengthens Technology Patent Portfolio

LEXINGTON, Mass., June 9, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced that the U.S. Patent and Trademark Office has granted U.S. Patent No. 8,735,557, entitled "Activated Sialic Acid Derivatives for ...



May 29, 2014
Xenetic Biosciences to Present at the Third Annual Marcum MicroCap Conference

LEXINGTON, Mass., May 29, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announced today that the Company will be a featured presenter at the 3rd Annual Marcum MicroCap Conference on Thursday, May 29, 2014 in New York City a...



May 21, 2014
Xenetic Biosciences Announces First Quarter 2014 Financial Results and Business Update

LEXINGTON, Mass., May 21, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today reported financial results for the quarter ended March 31, 2014. Scott Maguire, CEO of Xenetic Biosciences said, "Having been appointed CEO o...



May 12, 2014
Xenetic Biosciences Announces Positive Phase 1 Clinical Results for PSA-Oxyntomodulin for the Treatment of Type II Diabetes and Obesity

LEXINGTON, Mass., May 12, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced positive results from a Phase 1 clinical trial of PSA-Oxyntomodulin for the treatment of Type II Diabetes, a highly prevalent and...



May 5, 2014
Xenetic Biosciences Appoints Industry Veteran Mark Leuchtenberger as Chairman of the Board of Directors

LEXINGTON, Mass., May 5, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, today announced the appointment of Mark Leuchtenberger as Non-Executive Chairman of the Board of Directors. Scott Maguire, CEO of Xenetic Biosciences sai...



Apr 16, 2014
Xenetic Biosciences Announces Full Year 2013 Financial Results and Business Update

LEXINGTON, Mass., April 16, 2014 (GLOBE NEWSWIRE) -- Xenetic BioSciences (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel orphan oncology therapeutics, today reported financial results for the year-ended December 31, 2013. "The past several months have been pivotal for Xenetic as we have m...



Apr 7, 2014
Xenetic Biosciences Announces Positive Phase 1 Clinical Data for PulmoXen(TM) for Treatment of Cystic Fibrosis

LEXINGTON, Mass., April 7, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced the positive results from its Phase I clinical trial of PulmoXenTM for the treatment of cystic fibrosis. The single center, open...



Apr 4, 2014
Xenetic Biosciences Appoints Darlene Deptula-Hicks to Board of Directors

LEXINGTON, Mass., April 4, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, today announced the appointment of Darlene Deptula-Hicks to its Board of Directors. Scott Maguire, CEO of Xenetic Biosciences said: "We are pleased to ...



Mar 4, 2014
Xenetic Biosciences Announces Opening of Corporate Headquarters and R&D Facility in Lexington, MA

LEXINGTON, Mass., March 4, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced the opening of its new corporate headquarters and research and development facility in Lexington, MA. Xenetic, in collaboration ...



Feb 14, 2014
Xenetic Biosciences Announces Ticker Symbol Change to XBIO

LEXINGTON, Mass., Feb. 14, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, today announced that its common stock has commenced trading under new ticker symbol "XBIO" on the OTC Bulletin Board (OTCBB). Since changing its...



Feb 10, 2014
Xenetic Biosciences Appoints Timothy Cote, MD, MPH, Former Head of FDA Orphan Drug Division, to Board of Directors

LEXINGTON, Mass., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:GAIFD), a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, today announced the appointment of Timothy Coté, MD, MPH, to the company's Board of Directors. Scott Maguire, CEO of Xenetic Biosciences said, "W...



Jan 30, 2014
Xenetic Biosciences Announces Restructured Licensing Agreement With Baxter Now Totaling Up to $100 Million, in Addition to $10 Million Equity Investment

LEXINGTON, Mass., Jan. 30, 2014 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:GAIFD), a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics, today announced that it has received a direct investment of $10 million from Baxter International, Inc. and has agreed to a restructuring of certain finan...

[holly_dog] 24/6/2014 16:27

Vol is currently 110k, some big 20k/30k buys have gone through. It looks like on Level 2 someone wants to keep it trading in this range. Entities definitely looking for shares. As you say news is imminent, I suspect we will get a NASDAQ announcement.

[buywell2] 24/6/2014 16:18

Nearly hit $1 today

Phase 2 Clinical Trial results out next week just might do the trick

I am very happy with $1 for the time being

That is about 22p a share old money so I reckon most other UK shareholders will be also

Someone want to do the maths more spot on feel free

Not many shares to be had is pushing up the price on VOLS of less than 20k

[buywell2] 23/6/2014 10:30

Xenetic are still an unknown newbe in the states for the most part

EPO results need to be broadcast far and wide to achieve maximum impact

Let's hope an auction then takes place for the out-license of it that then follows with a nice fat upfront fee to pay for the NASDAQ listing and next few years of our own 'in house' clinical trials of Orphan Status drug compounds using our own patented technology and IP.

[holly_dog] 20/6/2014 14:48

There are MMs hungry for stock..ATDF have now appeared on the bid, 15k order and have already gobbled 15k. According to Google search they act for E-Trade and UBS

[holly_dog] 20/6/2014 08:38

I think we have to accept that there is going to be extreme volatility until we get to NASDAQ. If we can get a positive Aus EPO trial out and the steps to NASDAQ it should help to at least support the volatility going in the right direction.

[buywell2] 20/6/2014 07:27

Should be by the end of this month

Was that u buying yesterday Dr B ?

circa 80k shares BUY = 300% rise

The other side of the OTC coin eh

[jammytass] 19/6/2014 19:27

yip when i the news due out

[buywell2] 19/6/2014 19:18

The sooner ErepoXen news comes out the better

[jammytass] 19/6/2014 19:18

big rise in usa